U-Shaped Association Between Serum Uric Acid Level and Hypertensive Heart Failure: A Genetic Matching Case-Control Study

Xu, Hongxuan; Wang, Quan; Liu, Yunqing; Meng, Ling‐Bing; Long, Huanyu; Wang, Li; Liu, Deping

doi:10.3389/fcvm.2021.708581

Cited by 3 publications

(1 citation statement)

References 39 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the biochemistry standpoints, the fluctuation of sugar blood pressure and uric acid triggers the NLRP3 inflammasome or IL6 activity, leading to HD. Xu et al that the high or low uric acid were predictive of the HD such as heart failure (not the uric acid per sec) ( 25 ). Meanwhile, the fluctuation of fasting blood glucose (diabetes) and total cholesterol levels (hyperlipidemia), sBP (hypertension), and body mass index (gout) was an independent predictor of HD (not the BP, sugar per sec) ( 26 , 27 ).…”

Section: Methodsmentioning

confidence: 99%

Colchicine Is a Weapon for Managing the Heart Disease Among Interstitial Lung Disease With Viral Infection: Have We Found the Holy Grail?

Yeh

Hung

Lin

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundThis study investigated the effect of colchicine use on the risks of heart disease (HD), pericarditis, endocarditis, myocarditis, cardiomyopathy, cardiac arrhythmia, and cardiac failure in patients having interstitial lung disease (ILD) with virus infection (ILD cohort).MethodsWe retrospectively enrolled ILD cohort between 2000 and 2013 from the Longitudinal Health Insurance Database and divided them into colchicine users (n = 12,253) and colchicine non-users (n = 12,253) through propensity score matching. The event of interest was the diagnosis of HD. The incidence of HD was analyzed using multivariate Cox proportional hazards models between colchicine users and the comparison cohort after adjustment for age, sex, medication, comorbidities, and index date based on the time-dependent analysis.ResultsColchicine users had a significantly lower risk of HD (aHR = 0.87, 95% confidence interval (CI]) = 0.82–0.92) than did the colchicine non-user. For colchicine non-users as the reference, the aHR (95% CI) of the patients who received colchicine of 2–7, 8–30, 31–150, and > 150 days were 0.89 (0.81–0.98), 0.84 (0.76–0.94), 090 (0.80–0.99), and 0.83 (0.74–0.93), respectively; regardless of duration use, the lower risk of HD persisted in colchicine users. The cumulative incidence of HD in colchicine users was significantly lower than that in the colchicine non-users (log-rank p < 0.001).ConclusionThe addition of short-term or long-term colchicine to standard medical therapy may have benefits to prevent the HD among the ILD patients concurrent with a virus infection or comorbidities even in elderly patients.

show abstract

Section: Methodsmentioning

confidence: 99%